Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Agnes Buntinx"'
Autor:
Françoise. Brunner-Ferber, Erik A. Lippa, Norbert Pfeiffer, Daniel J. Holder, Agnes Buntinx, Béchetoille A, Frans P. Gunning, Jurgen Gerling, Coleen Clineschmidt, Franz Grehn, Erik L. Greve
Publikováno v:
Eye. 6:525-529
Sezolamide, a potent topical carbonic anhydrase inhibitor previously known as MK-417, was studied to determine its ocular hypotensive activity in patients with elevated intraocular pressure while on continuing therapy with topical timolol. This was a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0205d0c3a9f14b0f6acb2d3c0a605b64
https://doi.org/10.1038/eye.1992.111
https://doi.org/10.1038/eye.1992.111
Publikováno v:
European Urology. 20:82-86
Finasteride is a potent competitive 5 alpha-reductase inhibitor, active at a dose as low as 1 mg/day. After a single dose, the effects on 5 alpha-reductase last as long as 7 days. Both hepatic and target tissue 5 alpha-reductase are inhibited. Plasma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f49d2badadaa61ae5afa9972414e558
https://doi.org/10.1159/000471752
https://doi.org/10.1159/000471752
Autor:
Peggy H. Wong, Barry J. Gertz, Jef Arnout, Marleen Depré, Anne Van Hecken, Wesley Tanaka, David L. Ebel, Kathleen Wynants, Paul J. De Schepper, Aimee Dallob, Inge De Lepeleire, Agnes Buntinx, Jules I. Schwartz
Publikováno v:
Journal of clinical pharmacology. 40(10)
Steady-state inhibitory activity of rofecoxib (Vioxx) on COX-2 versus COX-1 was compared with that of commonly used nonsteroidal anti-inflammatory drugs (NSAIDs) in 76 healthy volunteers randomized to placebo, rofecoxib 12.5 mg qd, rofecoxib 25 mg qd
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f8d33a4240f67a7344fdfb872d7c180
https://pubmed.ncbi.nlm.nih.gov/11028250
https://pubmed.ncbi.nlm.nih.gov/11028250
Publikováno v:
Clinical pharmacology and therapeutics. 53(5)
MK-886, a leukotriene biosynthesis inhibitor, was evaluated in double-blind, placebo-controlled, randomized single- and multiple-dose studies in 12 and 24 healthy male subjects, respectively. The effects of a single dose (250, 500, and 750 mg) and mu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ae80cc596363384c5a4d9fbada120a3
https://pubmed.ncbi.nlm.nih.gov/8387904
https://pubmed.ncbi.nlm.nih.gov/8387904
Publikováno v:
Clinical pharmacology and therapeutics. 52(4)
A four-period, two-panel single rising-dose study (0.1 to 100 mg) was conducted in healthy men to investigate the pharmacodynamics and tolerability of L-654,066, a steroid 5 alpha-reductase inhibitor. Within each panel, six subjects received L-654,06
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5753680b733bb2d9c5d9753e7e302f51
https://pubmed.ncbi.nlm.nih.gov/1424413
https://pubmed.ncbi.nlm.nih.gov/1424413
Autor:
J.-W.J. Lammers, Marc Decramer, F.M.J. Van den Elshout, I De Lepeleire, P. Van Daele, Agnes Buntinx, B. Friedman
Publikováno v:
Pulmonary Pharmacology, 5(2), 121-125. Academic Press
The safety, tolerability and bronchodilator properties of inhaled verlukast (MK-0679), a new potent and selective LTD4-receptor antagonist, were studied in 12 asthmatic subjects with more than 15% increase in FEV1 after salbutamol inhalation. On thre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::792e9d4039208c50bf54ed7c7d4805bf
https://pure.eur.nl/en/publications/6e526688-4629-4ae8-bbf1-13002010f37f
https://pure.eur.nl/en/publications/6e526688-4629-4ae8-bbf1-13002010f37f
Autor:
J. Y. K. Hsieh, Marleen Depré, A. Van Hecken, P. J. De Schepper, I De Lepeleire, Agnes Buntinx, D. J. Margolskee, J. D. Rogers
Publikováno v:
European journal of clinical pharmacology. 43(4)
We have studied the tolerability and plasma drug profiles of a leukotriene D4 receptor antagonist, MK-571, given intravenously and as an oral solution in two separate trials. Study I (i.v.) involved 2 panels of 6 healthy men in a double-blind, altern
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53143d18449335dde1ebe2ac6f196dfd
https://pubmed.ncbi.nlm.nih.gov/1451725
https://pubmed.ncbi.nlm.nih.gov/1451725
Autor:
Marcel E. Van Der Straeten, Johan Kips, Inge De Lepeleire, Guy Joos, Agnes Buntinx, Romain Pauwels, Dorothy J. Margolskee
Publikováno v:
The American review of respiratory disease. 144(3 Pt 1)
MK-571 is a novel leukotriene D4/E4 (LTD4/E4) receptor antagonist. The ability of MK-571 to inhibit LTD4-induced bronchoconstriction was examined both in six healthy volunteers and in six asthmatic subjects in a double-blind, placebo-controlled, rand
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::360ab8bd0842db833356427888a14d01
https://pubmed.ncbi.nlm.nih.gov/1892302
https://pubmed.ncbi.nlm.nih.gov/1892302
Autor:
Anne Van Hecken, Inge De Lepeleire, Julianne Imperato-McGinley, Elizabeth Stoner, Josephine R. Carlin, Paul J. De Schepper, Agnes Buntinx, Mary H. Gressi
Publikováno v:
Steroids. 56(9)
The hormonal effects following the acute (single dose) administration of a 4-azasteroid inhibitor of 5 alpha-reductase (MK-906) were evaluated in 10 healthy male volunteers. Marked suppression of serum dihydrotestosterone (DHT) was observed after the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dca113bbccea4b40370cdfbaca32b58e
https://pubmed.ncbi.nlm.nih.gov/1666698
https://pubmed.ncbi.nlm.nih.gov/1666698
Autor:
Erik L. Greve, Jean-Luc George, Alain M. Bron, Frans P. Gunning, Erik A. Lippa, Jean G. Royer, Coleen Clineschmidt, F. Brunner-Ferber, Agnes Buntinx, Pierre Lesure, Jacques Flament, Daniel Sirbat, Deborah L. Panebianco, Claude Bénichou
Publikováno v:
Archives of Ophthalmology-New Series
Archives of Ophthalmology-New Series-, American Medical Association, 1991, 109 (1), pp.50-53
Archives of Ophthalmology-New Series-, American Medical Association, 1991, 109 (1), pp.50-53
International audience; The multiple-dose twice-daily efficacy of the topical carbonic anhydrase inhibitor MK-927, a racemic compound, was compared with that of its pharmacologically more active S-enantiomer in a four-center, double-masked, randomize
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4d86317842da61275edcfd15efa8b3a
https://hal.inrae.fr/hal-02712312
https://hal.inrae.fr/hal-02712312